MEDICAMEN Biotech Limited is engaged in manufacturing of pharmaceutical formulations. The Company is a manufacturer and supplier of a range of products, such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non-beta lactum), ointment and oral rehydration solution (ORS). Its tablets include Biperiden Hydrochloride Tablets USP, Bromhexine Hydrochloride Tablets, Calcium Carbonate Tablets USP, Calcium Gluconate Tablets USP and Captopril Tablets BP. Its capsules include Alfacalcidol Capsules, Artemether Capsules, Acebrophylline Capsules, Amoxycillin Capsules and Calcium Dobisilate Capsules. Its dry syrup includes Cefaclor Oral Suspension BP, Cefadroxil Oral Suspension BP and Cefadroxil Oral Suspension USP. It has two finished formulation plants, one at Bhiwadi (Rajasthan) and other at Haridwar (Uttarakhand). At Haridwar, the Company manufactures non-betalectum range of products, including iron-folic acid tablets, ointments, lotions, mouth wash and dental care.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.